Bristol-Myers Squibb brings Opdivo to a joint immuno-oncology program with Nektar’s new T cell amplifier
Six years ago, when Steve Doberstein took over as chief scientific officer at Nektar Therapeutics, he set up a new biologics research group with an …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
